Remicade copy to be shipped abroad within a year, Biocad says

Following the approval of a Remicade (infliximab) biosimilar from Russian company Biocad in its home country last month, the company anticipates that this product will enter other markets at the end of 2018 or in early 2019.

Used to treat immune-mediated inflammatory diseases, the original Remicade is the top-selling pharmaceutical product of Janssen, part of the US healthcare giant Johnson & Johnson (NYSE: JNJ). Its cost varies in different countries from $400 to $1,500 per 100mg.

Biosimilars offer the opportunity to bring prices down for patients with rheumatoid arthritis, ankylosing spondylitis, bowel inflammatory disease, and other severe autoimmune disorders.